Ascendis Pharma A/S $ 146.91 3.46 (2.41%)
Volume:
232,602
Avg Vol (1m):
193,341
Market Cap $:
7.90 Bil
Enterprise Value $:
6.84 Bil
PE Ratio:
0.00
PB Ratio:
6.92
Financial Strength | 6/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 27.94 | ||
Equity-to-Asset | 0.91 | ||
Debt-to-Equity | 0.04 | ||
Debt-to-EBITDA | -0.12 | ||
Piotroski F-Score | 2 | ||
Altman Z-Score | 41.64 | ||
Beneish M-Score | -3.96 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -3355.53 | ||
Net Margin % | -4051.54 | ||
ROE % | -56.01 | ||
ROA % | -49.81 | ||
ROC (Joel Greenblatt) % | -662.07 | ||
3-Year Revenue Growth Rate | 20.5 | ||
3-Year EBITDA Growth Rate | -23 | ||
3-Year EPS without NRI Growth Rate | -24.2 |
ASND
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 6.92 | ||
PS Ratio | 716.65 | ||
EV-to-EBIT | -19.53 | ||
EV-to-EBITDA | -20.07 | ||
EV-to-Revenue | 676.67 | ||
Current Ratio | 14.8 | ||
Quick Ratio | 14.8 | ||
Days Sales Outstanding | 115.77 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -14 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 6.94 | ||
Earnings Yield (Greenblatt) % | -5.13 |